BEGIN Novel ImagiNG Biomarkers

PHASE4RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

November 1, 2028

Study Completion Date

November 1, 2028

Conditions
Cystic Fibrosis
Interventions
DRUG

129Xe

Rapid spatial mapping of lung, liver, and pancreatic structure and function is now possible with a combination of hyperpolarized 129Xe and traditional proton MRI, all absent sedation and ionizing radiation.

Trial Locations (3)

22903

RECRUITING

University of Virginia, Charlottesville

45229

ACTIVE_NOT_RECRUITING

Carrie Stevens, Cincinnati

66160

ACTIVE_NOT_RECRUITING

University of Kansas Medical Center, Kansas City

All Listed Sponsors
collaborator

University of Kansas

OTHER

collaborator

University of Iowa

OTHER

collaborator

University of Virginia

OTHER

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT05517655 - BEGIN Novel ImagiNG Biomarkers | Biotech Hunter | Biotech Hunter